Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Crumbs cell polarity complex component 3 (CRB3) is a highly conserved, small transmembrane protein predominantly expressed in mammalian epithelial tissues, where it localizes to the apical membrane and is a core member of the Crumbs apical polarity complex[1][2][3]. CRB3 interacts with scaffolding proteins such as PALS1 and PATJ to form the Crumbs complex, which is essential for establishing and maintaining apical-basal polarity in epithelial cells and regulating the structure and function of tight junctions[1][2][3]. Through its cytoplasmic tail, CRB3 binds directly to partners like Par6 and is involved in regulating actin dynamics, tissue morphogenesis, and the Hippo/YAP pathway, influencing cell proliferation and organ size[1][2][3]. While not traditionally classified as a direct therapeutic target such as receptors, enzymes, or transporters, CRB3 has been implicated in cancer biology, acting as a putative tumor suppressor and modulating cell polarity loss associated with cancer progression[4]. Knockout or dysfunction of CRB3 can result in developmental defects and altered epithelial tissue organization, with studies in knockout mice indicating abnormalities in lung development[1]. **Notes:** - CRB3 is not a classic therapeutic target like a receptor or enzyme, and no drugs are currently known to directly target or modulate its activity[1][2][3][4]. - There are no established biomarkers or safety concerns specifically associated with CRB3 modulation. - Its main biological importance lies in fundamental epithelial tissue organization and the regulation of cell polarity rather than as a druggable target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Crumbs cell polarity complex component 3 (CRB3).